Opportunities in The (Overpriced) Japan Pharma Sector
As a defensive sector, Japan’s pharmaceutical sector has had an up-and-down time of it during the Abe era. In the early days of Abenomics, the...
150 Views
Innovation to Help Maintain HIV Franchise Market Share and Weather Harsh Domestic Market Conditions
Continuous innovation at HIV Franchise to not only help defend market share…. Concerns about competition from Gilead Sciences Inc (GILD US)'s,...
121 Views
Shionogi FY17 Earnings - First Glance
Shionogi & Co Ltd (4507 JP) reported FY17 results on May 09, 2018 HIV franchise royalties drove FY17 topline growth and gross margin expansion...
110 Views
Japan Pharmaceuticals: FY17e Earnings Preview (II)
Shionogi & Co Ltd (4507 JP) - May 09, 2018FY18e Potential GuidanceHIV franchise continues its growth trajectory, however, genericization of its...
116 Views
Japan Pharmaceuticals: The Week that Was…
Nippon Shinyaku Co Ltd (4516 JP) @ ¥ 8,480 (up ~18% week-to-date) vs. our TP ¥ 8,600. We recommend booking profit at current levels. Takeda...
112 Views